FTC Says Likely Pay-For-Delay Deals Are Down
The Federal Trade Commission said Thursday that despite an increase in the number of settlements between branded and generic-drug makers in 2016, fewer deals included the types of reverse payments that...To view the full article, register now.
Already a subscriber? Click here to view full article